age-related macular degeneration
Conditions
Interventions
IBI302 treatment group:IBI302 treatment
EYLEA Group:Treatment of EYLEA
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. BCVA greater than 0.025 and less than or equal to 0.5, that is, greater than 1 letter number and less than or equal to 70 letter number (Snellen vision 20/40-20/800); 2. Patients secondary to WAMD with active fibrosis lesions and with fibrous scar area accounting for more than 50% of the whole lesion area; 3.3 No systemic or local anti-VEGF therapy or hormone therapy was given within a month; 4. The patient is younger than 80 years old and older than 50 years old.
Exclusion criteria
Exclusion criteria: 1. GA lesions or "atrophic fibrous lesions" progressing from AMD eyes: retinal thickness less than 100 microns; 2. The lesions that meet the relevant characteristics of OCT but lack the fundus characteristics of "clearly demarcated yellow-white raised tissue"; 3. Patients who have previously undergone intraocular surgery (such as vitrectomy) (excluding drug injection and cataract surgery for more than 3 months); 4. Poor refractive interstitial, poor general condition (hypertension greater than 160/100, glycation greater than 7.5%, coagulation disorder, etc.); 5. Other diseases involving the fundus and fovea, such as epimacular membrane, macular hole, RVO, etc.; 6. Patients with cardiovascular events within 6 months, tumor patients who need treatment, and patients with mental illness; 7. Those who are considered unsuitable by the researchers, such as psychological problems, disputes, economic problems, those who cannot understand communication, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity; | — |
Countries
China
Contacts
Public ContactSun Xiaodong
Shanghai General Hospital
Outcome results
None listed